Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib + Decitabine + Venetoclax in AML
NCT04493099Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2020
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alvocidib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2020; status: withdrawn.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04493099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493099.